Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences reported third-quarter 2026 financial results and provided a pipeline update on its clinical-stage investigational molecules. The company highlighted its focus on developing differentiated molecules and combination therapies for cancer and immune diseases. In October, Arcus demonstrated robust and durable HIF-2 activity for the first time. This update covers the company's progress through September 30, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Reported robust and durable HIF-2 results.
  • Pipeline includes promising investigational molecules.
  • Focus on cancer and immune diseases shows potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~17 mo
Medium dilution risk
Lead asset
Etrumadenant
Phase 2 · Prostatic Neoplasms, Castration-Resistant

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “In October, we showed for the first time that robust and durable HIF-2

Frequently Asked Questions

What were the financial results for Q3 2026?

Arcus Biosciences reported its third-quarter financial results for 2026.

What is the focus of Arcus Biosciences?

The company focuses on developing therapies for cancer and immune diseases.

What updates were provided on the pipeline?

Arcus highlighted advancements in its clinical-stage investigational molecules.

What notable results were reported?

The company reported robust and durable results for HIF-2.

ShareAdd on Google
Tags: RCUS Arcus Biosciences HIF-2 clinical-stage cancer therapies
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~17 mo
Medium dilution risk
Lead asset
EtrumadenantPhase 2
Prostatic Neoplasms, Castration-Resistant →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →